Structural basis for the neutralization of SARS-CoV-2 by an antibody from a convalescent patient

The COVID-19 pandemic has had an unprecedented health and economic impact and there are currently no approved therapies. We have isolated an antibody, EY6A, from an individual convalescing from COVID-19 and have shown that it neutralizes SARS-CoV-2 and cross-reacts with SARS-CoV-1. EY6A Fab binds th...

Full description

Bibliographic Details
Main Authors:	Zhou, D, Duyvesteyn, HME, Chen, C-P, Huang, C-G, Chen, T-H, Shih, S-R, Lin, Y-C, Cheng, C-Y, Cheng, S-H, Huang, Y-C, Lin, T-Y, Ma, C, Huo, J, Carrique, L, Malinauskas, T, Ruza, RR, Shah, PNM, Tan, TK, Rijal, P, Donat, RF, Godwin, K, Buttigieg, KR, Tree, JA, Radecke, J, Paterson, NG, Supasa, P, Mongkolsapaya, J, Screaton, GR, Carroll, MW, Gilbert-Jaramillo, J, Knight, ML, James, W, Owens, RJ, Naismith, JH, Townsend, AR, Fry, EE, Zhao, Y, Ren, J, Stuart, DI, Huang, K-YA
Format:	Journal article
Language:	English
Published:	Springer Nature 2020

Structural basis for the neutralization of SARS-CoV-2 by an antibody from a convalescent patient

Similar Items